Bharat Immunologicals

23.49
+0.31
(1.34%)
Market Cap
101.44 Cr
EPS
-3.95
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
35.88
52 Week Low
19.00
PB Ratio
-3.08
Debt to Equity
0.00
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,751.50
#1 4,20,243.52
34.43
#1 49,887.20
12.06
#1 9,648
13.77
56.15
5,640.00
1,49,724.28
73.95
8,184.00
0.89
1,600
#1 64.53
49.32
1,515.20
1,22,369.82
24.22
26,520.70
14.17
4,155
47.38
58.14
3,254.80
1,10,157.22
58.55
10,785.70
11.59
1,656
13.54
57.00
2,581.60
1,06,511.27
50.98
10,615.60
19.57
1,942
-16.38
65.51
1,163.60
97,097.23
#1 18.01
28,905.40
12.36
5,578
1.69
53.92
1,937.20
88,441.11
30.81
20,141.50
#1 19.94
1,936
38.82
44.61
831.55
83,673.39
18.24
19,831.50
13.82
3,831
29.92
39.09
1,171.60
68,046.72
18.66
29,559.20
17.55
3,169
-10.04
56.33
30,690.00
65,214.11
48.91
6,097.20
10.80
1,201
16.01
56.24
Growth Rate
Revenue Growth
-40.38 %
Net Income Growth
94.32 %
Cash Flow Change
125.85 %
ROE
133.81 %
ROCE
357.22 %
EBITDA Margin (Avg.)
577.05 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
Revenue
147
129
125
36
88
68
87
80
47
9
Expenses
143
133
112
43
93
77
106
83
63
25
EBITDA
4
-4
14
-7
-5
-9
-19
-4
-16
-17
Operating Profit %
2 %
-4 %
10 %
-24 %
-11 %
-16 %
-24 %
-6 %
-41 %
-13 %
Depreciation
1
1
1
0
0
0
0
0
0
0
Interest
1
5
4
1
2
5
5
6
7
8
Profit Before Tax
2
-9
9
-8
-7
-14
-24
-10
-23
-25
Tax
1
-3
3
-4
-2
-4
-6
-1
-6
0
Net Profit
2
-6
7
-4
-6
-10
-18
-9
-17
-18
EPS in ₹
0.36
-1.44
1.51
-0.99
-1.34
-2.36
1.10
-2.03
-3.95
-4.20

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
Total Assets
80
68
59
53
125
127
104
213
186
Fixed Assets
6
6
5
5
5
5
4
116
115
Current Assets
74
60
47
38
99
93
34
65
33
Capital Work in Progress
0
0
0
0
0
0
32
0
0
Investments
0
0
0
0
0
0
0
0
0
Other Assets
74
63
53
48
120
122
68
97
70
Total Liabilities
80
68
59
53
125
127
104
213
186
Current Liabilities
35
30
14
13
89
101
64
101
91
Non Current Liabilities
4
3
3
3
6
6
6
6
6
Total Equity
41
35
42
38
31
21
34
105
88
Reserve & Surplus
-2
-8
-1
-6
-13
-23
-9
62
45
Share Capital
43
43
43
43
43
43
43
43
43

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
Net Cash Flow
7
-10
-20
1
-1
1
0
3
-3
Investing Activities
0
1
1
-1
1
1
1
1
1
Operating Activities
8
-9
-17
3
-32
34
12
-42
11
Financing Activities
-1
-2
-3
-1
31
-34
-12
45
-15

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Promoter
59.25 %
59.25 %
59.25 %
59.25 %
59.25 %
59.25 %
59.25 %
59.25 %
59.25 %
59.25 %
59.25 %
59.25 %
59.25 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
37.32 %
37.50 %
38.51 %
39.58 %
38.77 %
39.15 %
39.11 %
38.86 %
38.97 %
39.13 %
39.30 %
39.35 %
39.47 %
Others
3.43 %
3.25 %
2.24 %
1.17 %
1.97 %
1.59 %
1.63 %
1.88 %
1.77 %
1.61 %
1.45 %
1.39 %
1.28 %
No of Share Holders
33,938
38,195
36,799
36,869
36,323
35,695
35,411
36,242
35,535
34,818
34,201
34,910
35,313

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Board Meeting Intimation for Intimation Of Date Of Board Meeting On 16.08.2024 Under Regulation 29 Of SEBI'S LODR.Aug 07, 2024
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 08.03.2024 Under Regulation 29 Of SEBI'S LODR.Feb 29, 2024
Compliance Of Regulation 34 Of LODR 2015 And Submission Annual Report For 34Th Annual General Meeting Scheduled On 29.12.2023.Dec 13, 2023
Compliance Of The Regulation Of LODR 2015 For The Intimation Of Book Closure Period (22.12.2023 To 29.12.2023) Of The Company In Respect Of 34Th Annual General Meeting Scheduled To Be Held On 29.12.2023.Nov 28, 2023
Submission Of Notice Of 34Th Annual General Meeting On 29.12.2023 As Compliance Of The Provision Of LODR 2015.Nov 28, 2023
Submission Of Unaudited Quarterly Financial Results Alongwith Limited Review Report For The Quarter And Half Year Ended September 2023 As Compliance Of LODR 2015Nov 01, 2023
Submission Of Unaudited Quarterly Financial Results Alongwith Limited Review Report For The Quarter Ended June 2023 As Compliance Of LODR 2015Nov 01, 2023
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 31St October 2023 Under Regulation 29 Of SEBI'S LODR.Oct 19, 2023
Submission Of Signed Audited Annual Accounts 2022-23 Alongwith Statutory Audit Report Thereof Provided By The Statutory Auditor Appointed By Comptroller & Auditor General Of India (C&AG).Sep 15, 2023
Submission Of Annual Accounts For The Financial Year Ended On 31.03.2023 And Is Under Audit Of Statutory Auditor Appointed By C&AGMay 31, 2023
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 10, 2023
Compliance Certificate Under Regulation 7(3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ending On 31.03.2023.May 10, 2023
Certificate From Practicing Company Secretary Under Regulation 40 (9) Of SEBI (LODR) Regulations 2015 For The Year Ended 31.03.2023Apr 27, 2023
Update on board meetingApr 17, 2023
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 17Th April 2023 Under Regulation 29 Of SEBI'S LODR.Apr 17, 2023
Submission Of Unaudited Quarterly Financial Results For The Quarter And Nine Months Ended December 2022 Along With Limited Review ReportFeb 10, 2023
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 09Th February 2023 Under Regulation 29 Of SEBI'S LODR.Feb 01, 2023
Clarification sought from Bharat Immunologicals & Biologicals Corporation LtdDec 27, 2022
Board Meeting Outcome for Submission Of Un-Audited Quarterly Financial Results For The Quarter Ended September 2022 And Limited Review Report Thereon As Per The Compliance Of LODR 2015Oct 17, 2022
Statement Of Investor Complaints For The Quarter Ended September 2022Oct 11, 2022
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 17Th October 2022Oct 06, 2022
Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI LODR 2015 For The Year 2021-22.Sep 29, 2022
Reg. 34 (1) Annual Report.Sep 23, 2022
Compliance Of The Regulation Of LODR 2015 For The Intimation Of Book Closure Period (23.09.2022 To 30.09.2022) Of The Company In Respect Of 33Rd Annual General Meeting Scheduled To Be Held On 30.09.2022.Sep 06, 2022
Submission Of Notice Of 33Rd Annual General Meeting On 30.09.2022 As Compliance Of The Provision Of LODR 2015.Sep 06, 2022
Board Meeting Outcome for Submission Of Un-Audited Quarterly Financial Results For The Quarter Ended June 2022 And Limited Review Report Thereon As Per The Compliance Of LODR 2015Aug 15, 2022
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 11Th August 2022 Under Regulation 29 Of SEBI'S LODR.Aug 03, 2022
Compliances-Reg.24(A)-Annual Secretarial ComplianceJul 13, 2022
Certificate From Practicing Company Secretary Under Regulation 40 (9) Of SEBI (LODR) Regulations 2015 For The Year Ended 31.03.2022Jun 15, 2022
Submission Of Reviewed Annual Financial Results For The Year Ended 31.03.2022May 31, 2022
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 30Th May 2022 Under Regulation 29 Of SEBI'S LODR.May 18, 2022
Statement Of Investor Complaints For The Quarter Ended March 2022Apr 08, 2022
Submission Of Limited Review Report Of The Quarterly Unaudited Financial Results For The Quarter Ended December 2021 Under Regulation 33(3)(C ) Of LODRFeb 09, 2022
Board Meeting Outcome for Submission Of Unaudited Quarterly Financial Results For The Quarter Ended December 2021 As Compliance Of LODR 2015Feb 09, 2022
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 8Th February 2022 Under Regulation 29 Of SEBI'S LODRJan 31, 2022
Shareholding for the Period Ended December 31, 2021Jan 31, 2022
Statement Of Investor Complaints For The Quarter Ended December 2021Jan 10, 2022
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)Dec 01, 2021
Submission Of Limited Review Report Of The Quarterly Unaudited Financial Results For The Quarter Ended September 2021 Under Regulation 33(3)(C ) Of LODR, Related Party Transaction - NILNov 15, 2021
Submission Of Limited Review Report Of The Quarterly Unaudited Financial Results For The Quarter Ended September 2021 Under Regulation 33(3)(C ) Of LODRNov 15, 2021
Reg. 34 (1) Annual ReportNov 08, 2021
Compliance Of The Regulation Of LODR 2015 For The Intimation Of Book Closure Period (23.11.2021 To 30.11.2021) Of The Company In Respect Of 32Nd Annual General Meeting Scheduled To Be Held On 30.11.2021.Nov 01, 2021
Submission Of Notice Of 32Nd Annual General Meeting On 30.11.2021 As Compliance Of The Provision Of LODR 2015Nov 01, 2021
Board Meeting Outcome for Submission Of Unaudited Quarterly Financial Results For The Quarter And Half Year Ended September 2021 As Compliance Of LODR 2015Oct 30, 2021
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 29Th October 2021 Under Regulation 29 Of SEBI'S LODR.Oct 22, 2021
Shareholding for the Period Ended September 30, 2021Oct 19, 2021
Statement Of Investor Complaints For The Quarter Ended September 2021Oct 11, 2021
Submission Of Limited Review Report On Unaudited Quarterly Financial Results For Quarter Ended June 2021In Compliance Of SEBI LODR Please.Aug 15, 2021
Compliances-Reg.24(A)-Annual Secretarial ComplianceAug 01, 2021
Submission Of Unaudited Quarterly Financial Results For The Quarter Ended June 2021 As Compliance Of LODR 2015.<BR>Jul 27, 2021

Technical Indicators

RSI(14)
Neutral
58.93
ATR(14)
Volatile
1.53
STOCH(9,6)
Neutral
60.90
STOCH RSI(14)
Overbought
96.78
MACD(12,26)
Bullish
0.31
ADX(14)
Weak Trend
14.28
UO(9)
Bearish
54.97
ROC(12)
Uptrend And Accelerating
14.70
WillR(14)
Neutral
-23.62